Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181597 · ClinicalTrials.gov registry record · Phase 2
Trilostane for Androgen-Independent Prostate Cancer
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00181597 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 24 participants.
The verdict
NCT00181597, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.
Interventions
- DRUG Hydrocortisone
- DRUG Trilostane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181597
The ClinicalTrials.gov registry entry for NCT00181597 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydrocortisone is the first listed.
NCT00181597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181597 about?
NCT00181597 is a clinical study titled "Trilostane for Androgen-Independent Prostate Cancer". The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.
What is the current status of trial NCT00181597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2004-03. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00181597?
The interventions under investigation include: Hydrocortisone (DRUG), Trilostane (DRUG).
Who is sponsoring clinical trial NCT00181597?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.